Glaucoma, Marijuana, & CBD Oil
As marijuana use becomes more accepted and increasingly legalized, glaucoma patients frequently ask if marijuana can really treat glaucoma. We need to explain some truths and dispel some myths.
Marijuana is legal for medical use in 30 US states and for recreational use in 9 US States. It’s legal across Canada for recreational use. Despite the relaxed attitude around marijuana, it is still classified by the federal Drug Enforcement Agency as a Schedule I controlled substance (the same category as heroin and LSD ).
Does Marijuana Lower Intraocular Pressure?
Marijuana’s ability to lower intraocular pressure (IOP) was discovered in the 1970s. Elevated IOP is the major risk factor for developing glaucoma and for the progression of glaucoma. Treatment is focused solely on reducing IOP. Many have wondered whether marijuana could be used as a therapy to lower IOP and prevent glaucoma from getting worse or causing blindness.
While marijuana does lower IOP, it has major drawbacks as a treatment for a chronic, long-term, disease like glaucoma:
- First, unlike glaucoma eyedrops (some of which are effective for up to 24 hours), smoking THC reduces eye pressure for only 3-4 hours. Marijuana would require 8-10 doses per day.
- This would cost more than typical glaucoma treatment
- The physical and mental side-effects of frequent marijuana use would reduce one’s productivity.
- Marijuana also impairs judgment and coordination, increases paranoia, elevates heart rate, and irritates the eyes.
Are There Long-Term Side Effects of Marijuana?
Marijuana can cause permanent lung damage when smoked, and possible permanent adverse effects on cognition and mental health. With regular use, tolerance to the eye pressure-lowering effects develops, meaning that increasing drug levels would be required to prevent progression of glaucoma. Moreover, lack of regulation and quality control makes efficacy and safety of marijuana unpredictable. Research efforts to develop THC eyedrops that can effectively lower eye pressure while minimizing side effects are being studied, but have not yet been successful.
What About CBD (cannabidiol) Oil?
New evidence has emerged showing that parts of the cannabis plant, specifically cannabidiol (CBD), the non-intoxicating, trendy component, may actually worsen glaucoma symptoms. Researchers at Indiana University published a study in the journal Investigative Ophthalmology & Visual Science that shows CBD increases pressure in the eye. This is problematic, they say, considering that CBD has become such a household name in American culture that many people, some of which may have or be at risk for glaucoma, are using it haphazardly as a natural, harmless medicine. But in reality, CBD could be destroying their overall eye health.
The Final Verdict
For these reasons, smoking marijuana or using CBD oil is not recommended as a medical treatment for glaucoma. If you use marijuana or CBD oil, let your ophthalmologist know since it may have an impact on your eye pressure readings. Also, it is very important to continue the glaucoma treatment recommended by your ophthalmologist. This treatment and regular monitoring can help you maintain your vision for the rest of your life.
Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study
Purpose: The purpose of this study was to assess the effect on intraocular pressure (IOP) and the safety and tolerability of oromucosal administration of a low dose of delta-9-tetrahydrocannabinol (Delta-9-THC) and cannabidiol (CBD).
Patients and methods: A randomized, double-masked, placebo-controlled, 4 way crossover study was conducted at a single center, using cannabis-based medicinal extract of Delta-9-THC and CBD. Six patients with ocular hypertension or early primary open angle glaucoma received a single sublingual dose at 8 AM of 5 mg Delta-9-THC, 20 mg CBD, 40 mg CBD, or placebo. Main outcome measure was IOP. Secondary outcomes included visual acuity, vital signs, and psychotropic effects.
Results: Two hours after sublingual administration of 5 mg Delta-9-THC, the IOP was significantly lower than after placebo (23.5 mm Hg vs. 27.3 mm Hg, P=0.026). The IOP returned to baseline level after the 4-hour IOP measurement. CBD administration did not reduce the IOP at any time. However, the higher dose of CBD (40 mg) produced a transient elevation of IOP at 4 hours after administration, from 23.2 to 25.9 mm Hg (P=0.028). Vital signs and visual acuity were not significantly changed. One patient experienced a transient and mild paniclike reaction after Delta-9-THC administration.
Conclusions: A single 5 mg sublingual dose of Delta-9-THC reduced the IOP temporarily and was well tolerated by most patients. Sublingual administration of 20 mg CBD did not reduce IOP, whereas 40 mg CBD produced a transient increase IOP rise.
Rog DJ, Nurmikko TJ, Young CA. Rog DJ, et al. Clin Ther. 2007 Sep;29(9):2068-79. doi: 10.1016/j.clinthera.2007.09.013. Clin Ther. 2007. PMID: 18035205 Clinical Trial.
Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Johnson JR, et al. J Pain Symptom Manage. 2010 Feb;39(2):167-79. doi: 10.1016/j.jpainsymman.2009.06.008. Epub 2009 Nov 5. J Pain Symptom Manage. 2010. PMID: 19896326 Clinical Trial.
Mansouri K, Silva SE, Shaarawy T. Mansouri K, et al. J Glaucoma. 2011 Oct;20(8):519-22. doi: 10.1097/IJG.0b013e3181f3eb34. J Glaucoma. 2011. PMID: 21048514 Clinical Trial.
Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, Allen P, Seal M, Langohr K, Farré M, Zuardi AW, McGuire PK. Martin-Santos R, et al. Curr Pharm Des. 2012;18(32):4966-79. doi: 10.2174/138161212802884780. Curr Pharm Des. 2012. PMID: 22716148 Review.
Rong C, Carmona NE, Lee YL, Ragguett RM, Pan Z, Rosenblat JD, Subramaniapillai M, Shekotikhina M, Almatham F, Alageel A, Mansur R, Ho RC, McIntyre RS. Rong C, et al. Expert Opin Drug Saf. 2018 Jan;17(1):51-54. doi: 10.1080/14740338.2017.1397128. Epub 2017 Oct 31. Expert Opin Drug Saf. 2018. PMID: 29082802 Review.
Cited by 38 articles
Mosaed S, Smith AK, Liu JHK, Minckler DS, Fitzgerald RL, Grelotti D, Sones E, Weinreb RN, Marcotte TD. Mosaed S, et al. Front Med (Lausanne). 2022 Jan 17;8:736792. doi: 10.3389/fmed.2021.736792. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35111768 Free PMC article.
Aebersold A, Duff M, Sloan L, Song ZH. Aebersold A, et al. Cell Physiol Biochem. 2021 May 14;55(S5):1-14. doi: 10.33594/000000371. Cell Physiol Biochem. 2021. PMID: 33984199 Free PMC article.
Vallée A, Lecarpentier Y, Vallée JN. Vallée A, et al. Int J Mol Sci. 2021 Apr 6;22(7):3798. doi: 10.3390/ijms22073798. Int J Mol Sci. 2021. PMID: 33917605 Free PMC article. Review.
Velayudhan L, McGoohan K, Bhattacharyya S. Velayudhan L, et al. PLoS Med. 2021 Mar 29;18(3):e1003524. doi: 10.1371/journal.pmed.1003524. eCollection 2021 Mar. PLoS Med. 2021. PMID: 33780450 Free PMC article.
Sholler DJ, Schoene L, Spindle TR. Sholler DJ, et al. Curr Addict Rep. 2020 Sep;7(3):405-412. doi: 10.1007/s40429-020-00326-8. Epub 2020 Jul 25. Curr Addict Rep. 2020. PMID: 33585159 Free PMC article.